Monofar (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monofar, is an iron supplement presented as a solution for injection for intravenous use. It treats iron deficiency anemia and related anemic conditions in patients who require parenteral iron therapy.

GNH USA supplies Monofar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Monofar is an intravenous iron preparation used to correct iron deficiency in several clinical settings. - Iron deficiency anemia: restores hemoglobin levels and replenishes body iron stores. - Anemia associated with chronic kidney disease: improves iron availability for erythropoiesis in CKD patients. - Anemia in inflammatory bowel disease: corrects iron deficiency when oral iron is ineffective.

Adverse reactions may occur with any intravenous iron product.

Common Side Effects: - Nausea - Headache - Infusion‑site pain or erythema - Dizziness - Transient hypotension - Metallic taste in the mouth

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Acute respiratory distress syndrome - Severe hypotension or shock - Marked elevation of serum ferritin or iron overload - Hemolysis - Severe skin rash or urticaria

When using Monofar, clinicians should observe several safety measures. - Assess iron status before administration: confirm diagnosis of iron deficiency anemia. - Monitor hemoglobin and ferritin levels: adjust therapy based on laboratory response. - Observe for hypersensitivity during infusion: be prepared to manage reactions. - Use caution in patients with active infection: iron may promote bacterial growth. - Avoid in patients with known hypersensitivity to ferric derisomaltose or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ferric derisomaltose may interact with other agents that affect iron metabolism or cardiovascular status.

Major Interactions (Avoid): - Concurrent use with other intravenous iron products: risk of iron overload. - Co‑administration with erythropoiesis‑stimulating agents: may increase hypertension risk. - High‑dose parenteral vitamin C: can increase free iron and oxidative stress.

Moderate Interactions (Monitor Closely): - Oral iron supplements given simultaneously: may affect absorption; separate dosing times. - Antacids containing aluminum or magnesium: may bind iron and reduce efficacy.